Study | Time point | Placebo group, n/N (%) | Adverse event/serious complication | Treatment group, n/N (%) | Adverse event/serious complication |
---|---|---|---|---|---|
Adverse effects | |||||
Christiaens et al (2002)8 | 2 days | 10/38 (26) | Gastrointestinal problems (n = 3), headache (n = 3), dizziness/fatigue (n = 3), sleep disturbances (n = 0), vaginal itching (n = 2), dermatological problems (n = 1), other (n = 2) | 9/40 (23) | Gastrointestinal problems (n = 4), headache (n = 2), dizziness/fatigue (n = 2), sleep disturbances (n = 1), vaginal itching (n = 1), dermatological problems (n = 0), other (n = 0) |
Brooks et al (1972)7 | 7 days | 1/20 (5) | General malaise (n = 1) | 7/24 (29) | General malaise (n = 1), sore mouth (n = 1), sore tongue (n = 2), black, furred tongue (n = 1), allergic skin rash (n = 1), vomiting (n = 1) |
Ferry et al (2007)10 | 6 weeks | (4) | Gastrointestinal reaction | (5–8) | Gastrointestinal reaction |
Serious complications | |||||
Christiaens et al (2002)8 | 2 days | 1/38 (3) | Pyelonephritis | None reported | None reported |
Ferry et al (2007)10 | 6 weeks | 1/20 (5) | Pyelonephritis | 1/24 (4) | Pyelonephritis |
Brooks et al (1972)7 | None reported | None reported | None reported | None reported |
↵a Some patients experienced >1 adverse event.